Skin cancer prevention by oral nicotinamide

口服烟酰胺预防皮肤癌

• 批准号: nhmrc : 1026977
• 负责人: A/Pr Pablo Fernandez Peñas
• 金额: $ 40.5万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/skin-cancer-prevention-oral-nicotinamide/110531
• 关键词: Skin; cancer; prevention; oral; nicotinamide

Skin cancer affects 60% of Australians. Nicotinamide (vitamin B3) prevents many of sunlight’s damaging effects and reduces premalignant keratoses by 35% compared to placebo in sun-damaged individuals. We now need to test whether nicotinamide can prevent skin cancer. Skin cancer patients will receive nicotinamide or placebo for 12 months and new cancers will be counted in each group. Nicotinamide is safe, widely available and an exciting opportunity for cost-effective skin cancer prevention.

皮肤癌影响了60%的澳大利亚人。烟酰胺（维生素B3）可以防止阳光的许多破坏性影响，并减少35%的癌前角化病相比，安慰剂在阳光受损的个人。我们现在需要测试烟酰胺是否可以预防皮肤癌。皮肤癌患者将接受烟酰胺或安慰剂治疗12个月，并将在每组中计数新发癌症。烟酰胺是安全的，广泛可用的，并且是具有成本效益的皮肤癌预防的令人兴奋的机会。